Grifols

Grifols, a Pharmaceutical Preparation Manufacturing company headquartered in Spain, reported total emissions of approximately 1.36 billion kg CO2e in 2025. This includes Scope 1 emissions of 121.88 million kg CO2e, market-based Scope 2 emissions of 83.89 million kg CO2e, and Scope 3 emissions of 1.15 billion kg CO2e.

Looking back, Grifols's total emissions were about 1.23 billion kg CO2e in 2024, 1.15 billion kg CO2e in 2023, and 1.62 billion kg CO2e in 2022.

Grifols demonstrates a strong commitment to climate action, with several reduction targets in place:

• Near-term targets: Grifols commits to reducing absolute Scope 1 and 2 GHG emissions by 42% by 2030, using 2022 as a baseline year. This target is aligned with the Science Based Targets initiative (SBTi) for a 1.5°C trajectory.
• Scope 3 reduction: The company also aims to reduce absolute Scope 3 GHG emissions from purchased goods and services, capital goods, fuel- and energy-related activities, and upstream transportation and distribution by 25% by 2030, also from a 2022 baseline.
• Net-zero ambition: Grifols is committed to achieving net-zero emissions for Scope 1 and 2 by 2050.
• Intensity targets: The company plans to deliver a 55% reduction in GHG emissions per production unit by 2030 compared to 2018 levels for both Scope 1 and Scope 2. Additionally, Grifols aims to reduce its Scope 1 and Scope 2 emissions by 30% from 2020 levels by 2030.